Skip to content
by Legal Desire
31 August 2024

Latham & Watkins Advises Arcus Biosciences in US$250 Million Growth Facility

Advising firms

Deal team

13 lawyers named
LawyerFirmSeniorityPracticeOffice
Haim Zaltzman Lead Latham & Watkins LLP Partner transactional Not stated
Mark Roeder Lead Latham & Watkins LLP Partner transactional Not stated
Trevor Church Latham & Watkins LLP Associate Not stated Not stated
Erin Cusenbary Latham & Watkins LLP Associate Not stated Not stated
Tyler Davis Latham & Watkins LLP Associate Not stated Not stated
John Williams Latham & Watkins LLP Partner corporate Not stated
Jekkie Kim Latham & Watkins LLP Partner intellectual property Not stated
Mizuna Sekine Latham & Watkins LLP Associate intellectual property Not stated
Eric Cho Latham & Watkins LLP Partner tax Not stated
Betty Pang Latham & Watkins LLP Partner healthcare Not stated
Chad Jennings Latham & Watkins LLP Counsel FDA/regulatory Not stated
Reza Mojtabaee-Zamani Latham & Watkins LLP Partner transaction Not stated
Kevin Zhang Latham & Watkins LLP Associate transaction Not stated

10 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.

REGISTER FREE SIGN IN

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value
USD 250m (US$250 million)
What the figure measures
Facility amount
Client
Arcus Biosciences, Inc.Borrower
Counterparties
Hercules Capital, Inc. (Lenders)